Trial intelligence / Profile preview

Acetazolamide for Visuomotor Learning in COPD at Altitude

NCT03165890Phase 4Completed

Sponsor
University of Zurich
Start
May 2017
Primary completion
Jul 2017
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Acetazolamide with Placebo (2 arms). Primary endpoints: Visuomotor learning performance, drug effect and Visuomotor learning performance, altitude effect. Started May 2017; status: completed.

02

Drugs

acetazolamide
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on NCT03165890.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03165890.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call